EUVIMEDEUVIMED entdecken
Crossref

DNA Nanobarrel‐Based Drug Delivery for Paclitaxel and Doxorubicin

Jiaoyang Wang, Tianyu Zhang, Xueqiao Li, Wenna Wu, Hui Xu, Xin-Ming Xu, Tao Zhang iD

ChemBioChem · 04.10.2023 · 24 (19)

DOI: 10.1002/cbic.202300424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 09.08.2023. Verfasst von Jiaoyang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacol…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Co‐delivery of anticancer drugs and target agents by endogenous materials is an inevitable approach towards targeted and synergistic therapy. Employing DNA base pair complementarities, DNA nanotechnology exploits a unique nanostructuring method and has demonstrated its capacity for nanoscale positioning and templated assembly. Moreover, the water solubility, biocompatibility, and modifiability render DNA structure suitable candidate for drug delivery applications. We here report single‐stranded DNA tail conjugated antitumor drug paclitaxel (PTX), and the co‐delivery of PTX, doxorubicin and targeting agent mucin 1 (MUC‐1) aptamer on a DNA nanobarrel carrier. We investigated the effect of tail lengths on drug release efficiencies and dual drug codelivery‐enabled cytotoxicity. Owing to the rapidly developing field of structural DNA nanotechnology, functional DNA‐based drug delivery is promising to achieve clinical therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNanoparticlesPaclitaxelDrug Delivery SystemsDoxorubicinDrug LiberationDNADrug CarriersCell Line, Tumor

Stichwörter der Autor:innen

DNA origamiDNA-drug conjugatebreast cancerchemotherapydrug delivery system

Substanzen

PaclitaxelAntineoplastic AgentsDoxorubicinDNADrug Carriers

Autor:innen und Institutionen

  • Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Ya…
  • Department of Applied Chemistry, School of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, China.

ORCID-Profile: Tao Zhang

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Wang, J., Zhang, T., Li, X., Wu, W., Xu, H., Xu, X. M., & Zhang, T. (2023). DNA Nanobarrel‐Based Drug Delivery for Paclitaxel and Doxorubicin. ChemBioChem, 24(19). https://doi.org/10.1002/cbic.202300424

Vancouver

Wang J, Zhang T, Li X, Wu W, Xu H, Xu XM, et al. DNA Nanobarrel‐Based Drug Delivery for Paclitaxel and Doxorubicin. ChemBioChem. 2023;24(19). doi:10.1002/cbic.202300424

BibTeX
@article{Wang2023,
  author = {Wang, Jiaoyang and Zhang, Tianyu and Li, Xueqiao and Wu, Wenna and Xu, Hui and Xu, Xin-Ming and Zhang, Tao},
  title = {DNA Nanobarrel‐Based Drug Delivery for Paclitaxel and Doxorubicin},
  journal = {ChemBioChem},
  year = {2023},
  volume = {24},
  number = {19},
  doi = {10.1002/cbic.202300424}
}
Kostenlos starten →